CNR1 and polycystic ovary syndrome: Abdominal obesity, dyslipidemia, and insulin resistance observed in women with PCOS and metabolic dysfunction have been associated with increased activity of the endocannabinoid system, while CNR1 blockade has been shown to decrease serum aminotransferase levels and liver inflammation biomarkers in women with PCOS [67].